Qiagen (QGEN) Stock
Key stats
- Market cap
- $10.39B
- Price / Earnings ratio
- 27.1x
- EPS (TTM)
- $1.84
- Volume
- Loading
- 52-week high
- $57.82
- 52-week low
- $32.53
- Dividend yield
- 9.34%
- Dividend amount (latest)
- $2.29
Source: third-party data provider, as of November 13, 2026
Compare with QGEN
Recent news

Do Options Traders Know Something About Qiagen Stock We Don't?
Do Options Traders Know Something About Qiagen Stock We Don't?
QGEN

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
QGEN

QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
QGEN

QIAGEN reports preliminary Q3 2026 results
QIAGEN reports preliminary Q3 2026 results
QGEN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 65.96
- MACD 12/26/9
- 1.29
- EMA 9 of MACD
- 1.46
- MACD histogram
- -0.17
- SMA 50
- $46.26
- Price above SMA 50
- EMA 50
- $47.03
- Price above EMA 50
- SMA 200
- $42.49
- Price above SMA 200
- EMA 200
- $44.30
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.58 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Do Options Traders Know Something About Qiagen Stock We Don't?
Do Options Traders Know Something About Qiagen Stock We Don't?
QGEN

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
QGEN

QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
QGEN Stock Alert: Halper Sadeh LLC is Investigating Whether QIAGEN N.V. is Obtaining a Fair Price for its Shareholders
QGEN

QIAGEN reports preliminary Q3 2026 results
QIAGEN reports preliminary Q3 2026 results
QGEN

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
QGEN

EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports
EQT in advanced talks to buy testing firm Qiagen, Bloomberg News reports
QGEN

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
QGEN

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
QGEN

QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
QGEN

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
QGEN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Qiagen
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jonathan M. Pratt | CEO & Member of Management Board | 1970 |
| Dr. Roland Sackers | CFO, MD & Member of Management Board | 1968 |
| Mr. Thierry L. Bernard | Member of Management Board | 1964 |
| Mr. Antonio Santos | Senior VP & Head of Global Operations | — |
| Mr. Daniel Wendorff CEFA, CIIA | VP & Head of Investor Relations | — |
| Mr. John Gilardi | VP & Head of Corporate Communications | — |
| Ms. Stephany Foster | Senior VP & Head of Human Resources | 1979 |
| Dr. Thomas Schweins | Senior Vice President of Life Science Business Area | — |
| Dr. Thomas Theuringer | Senior Director & Head of External Communications | — |
| Mr. Jean-Pascal Viola | Senior VP & Head of Corporate Strategy and Business Development | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 65.96
- MACD 12/26/9
- 1.29
- EMA 9 of MACD
- 1.46
- MACD histogram
- -0.17
- SMA 50
- $46.26
- Price above SMA 50
- EMA 50
- $47.03
- Price above EMA 50
- SMA 200
- $42.49
- Price above SMA 200
- EMA 200
- $44.30
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $47.00
- Average
- $51.20
- High
- $53.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.2 | +2.5 | ||||||||||
| 2022 | -8.9 | -0.5 | -1.5 | -8.2 | -0.8 | +4.8 | +3.7 | -8.4 | -8.7 | +3.7 | +12.5 | -1.2 |
| 2023 | -1.9 | -7.1 | +1.4 | -2.0 | +0.9 | -1.6 | +3.7 | -2.8 | -9.2 | -6.5 | +8.7 | +4.8 |
| 2024 | -3.0 | -3.0 | -1.1 | -0.4 | +1.1 | -6.6 | +10.6 | -0.2 | +2.9 | -6.3 | +0.8 | +2.0 |
| 2025 | -2.5 | -12.4 | +5.0 | +8.2 | +6.9 | +7.0 | +2.3 | -6.9 | -4.8 | +1.1 | +4.5 | -5.0 |
| 2026 | +18.8 | -4.6 | -18.0 | -14.4 | +6.8 | +8.1 | +5.8 | +2.3 | +0.9 | +19.5 | -0.1 |
Corporate actions
Upcoming
No upcoming corporate actions for QGEN



